Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C124969-250mg | 250mg | In stock | $23.90 | |
C124969-1g | 1g | In stock | $77.90 | |
C124969-5g | 5g | In stock | $195.90 | |
C124969-25g | 25g | In stock | $882.90 | |
C124969-100g | 100g | In stock | $3,175.90 |
5-Fluorouracil prodrug. Anticancer agent.
Synonyms | Capecitabine [USAN:USP:INN:BAN] | Pentyl (1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl)carbamate | pentyl 1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-fluoro-2-oxo-1,2-dihydropyrim |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | Thymidylate synthase inhibitor |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Toxic, refer to SDS for further information. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Capecitabine is a tumor-selective fluoropyrimidine carbamate which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU. |
ALogP | 0.6 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Pubchem Sid | 488183411 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488183411 |
IUPAC Name | pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate |
INCHI | InChI=1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1 |
InChi Key | GAGWJHPBXLXJQN-UORFTKCHSA-N |
Canonical SMILES | CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O |
Isomeric SMILES | CCCCCOC(=O)NC1=NC(=O)N(C=C1F)[C@H]2[C@@H]([C@@H]([C@H](O2)C)O)O |
WGK Germany | 3 |
Alternate CAS | 154361-50-9 |
PubChem CID | 60953 |
MeSH Entry Terms | capecitabine;N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine;Xeloda |
Molecular Weight | 359.35 |
DrugBank Ligand | DB01101 |
---|---|
PubChem CID | 60953 |
CAS Registry No. | 154361-50-9 |
ChEMBL Ligand | CHEMBL1773 |
Wikipedia | Capecitabine |
ChEBI | CHEBI:31348 |
DrugCentral Ligand | 480 |
PubChem SID | 488183411 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
I2220180 | Certificate of Analysis | Jul 18, 2024 | C124969 |
I2220181 | Certificate of Analysis | Jul 18, 2024 | C124969 |
I2220203 | Certificate of Analysis | Jul 18, 2024 | C124969 |
I2220202 | Certificate of Analysis | Jul 10, 2024 | C124969 |
F2425156 | Certificate of Analysis | Apr 02, 2024 | C124969 |
F2425157 | Certificate of Analysis | Apr 02, 2024 | C124969 |
F2216125 | Certificate of Analysis | Mar 20, 2024 | C124969 |
A2218303 | Certificate of Analysis | Nov 10, 2023 | C124969 |
A2218304 | Certificate of Analysis | Nov 10, 2023 | C124969 |
A2218311 | Certificate of Analysis | Nov 10, 2023 | C124969 |
A2218393 | Certificate of Analysis | Nov 10, 2023 | C124969 |
G2114196 | Certificate of Analysis | Apr 18, 2023 | C124969 |
G2114252 | Certificate of Analysis | Apr 18, 2023 | C124969 |
A2104034 | Certificate of Analysis | Oct 20, 2022 | C124969 |
A2416025 | Certificate of Analysis | Jul 12, 2022 | C124969 |
K1406006 | Certificate of Analysis | Jun 27, 2022 | C124969 |
Solubility | Soluble in water (26 mg/ml), ethanol (207 mg/ml), methanol (> 40%), DMF (~14 mg/ml), and DMSO (72 mg/ml at 25 °C). |
---|---|
Sensitivity | heat sensitive |
Specific Rotation[α] | 98° (C=1,MeOH) |
Melt Point(°C) | 123 °C(dec.) |
Pictogram(s) | GHS08, GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H341:Suspected of causing genetic defects H360:May damage fertility or the unborn child H350:May cause cancer |
Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P281:Use personal protective equipment as required. P362+P364:Take off contaminated clothing and wash it before reuse. P203:Obtain, read and follow all safety instructions before use. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P318:if exposed or concerned, get medical advice. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. |
WGK Germany | 3 |
Merck Index | 1754 |
1. Zhu Yan, Ding Zhechun, Wang Yini, Wu Qing, Chen Dongmei, Wang Luanhong, Li Yuancheng, Yao Yao, Huang Jiman, Li Yun, Wang Xiaojing, Lin Yanchun, Guan Tian, Zeng Haoyu, Li Congzhu. (2023) BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options. Frontiers in Oncology, 13 [PMID:38162496] [10.3389/fonc.2023.1239957] |
2. Ming Liu, Ran Cen, Ji-Hong Lu, Tie-Hong Meng, Chun-Rong Li, Carl Redshaw, Timothy J. Prior, Zhu Tao, Xin Xiao. (2022) Cucurbit[6]uril-based carbon dots for recognizing L-tryptophan and capecitabine. Materials Chemistry Frontiers, 6 (19): (2859-2868). [PMID:] [10.1039/D2QM00589A] |
3. Hanwen Liu, Ying Liu, Ting Zhou, Penghui Zhou, Jianguo Li, Anping Deng. (2022) Ultrasensitive and Specific Detection of Anticancer Drug 5-Fluorouracil in Blood Samples by a Surface-Enhanced Raman Scattering (SERS)-Based Lateral Flow Immunochromatographic Assay. MOLECULES, 27 (13): (4019). [PMID:35807264] [10.3390/molecules27134019] |
4. Ting Zhou, Guangzhao He, Changjia Hu, Kang Wu, Ying Liu, Jianguo Li, Anping Deng. (2022) Development of a highly sensitive and specific monoclonal antibody-based ELISA coupled with immuno-affinity extraction for the detection of anticancer drug 5-fluorouracil in blood samples. TALANTA, 249 (123655). [PMID:35696979] [10.1016/j.talanta.2022.123655] |
5. Zhouxuan Xiang, Ting Liu, Huimin Wang, Genxin Chen, Xiongbin Zhu, Tonghui Hao, Jiabing Ran, Changying Yang. (2022) Rational design of a supramolecular hydrogel with customizable pH-responsiveness on the basis of pH-induced ionization/protonation transition of BSA. Soft Matter, 18 (16): (3157-3167). [PMID:35380147] [10.1039/D1SM01589C] |
6. Shaoyu Tang, Lei Xu, Xiaolong Yu, Shuona Chen, Huanyong Li, Ying Huang, Junfeng Niu. (2021) Degradation of anticancer drug capecitabine in aquatic media by three advanced oxidation processes: Mechanisms, toxicity changes and energy cost evaluation. CHEMICAL ENGINEERING JOURNAL, 413 (127489). [PMID:] [10.1016/j.cej.2020.127489] |
1. Shi H et al.. (2014) Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.. Cancer Lett, 349 (2): (128-35). [PMID:24746899] |
2. Miwa M et al.. (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.. Eur J Cancer, 34 (8): (1274-81). [PMID:9849491] |
3. Terranova-Barberio M et al.. (2015) Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.. Oncotarget, [PMID:26735339] |
4. Zhu Yan, Ding Zhechun, Wang Yini, Wu Qing, Chen Dongmei, Wang Luanhong, Li Yuancheng, Yao Yao, Huang Jiman, Li Yun, Wang Xiaojing, Lin Yanchun, Guan Tian, Zeng Haoyu, Li Congzhu. (2023) BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options. Frontiers in Oncology, 13 [PMID:38162496] [10.3389/fonc.2023.1239957] |
5. Ming Liu, Ran Cen, Ji-Hong Lu, Tie-Hong Meng, Chun-Rong Li, Carl Redshaw, Timothy J. Prior, Zhu Tao, Xin Xiao. (2022) Cucurbit[6]uril-based carbon dots for recognizing L-tryptophan and capecitabine. Materials Chemistry Frontiers, 6 (19): (2859-2868). [PMID:] [10.1039/D2QM00589A] |
6. Hanwen Liu, Ying Liu, Ting Zhou, Penghui Zhou, Jianguo Li, Anping Deng. (2022) Ultrasensitive and Specific Detection of Anticancer Drug 5-Fluorouracil in Blood Samples by a Surface-Enhanced Raman Scattering (SERS)-Based Lateral Flow Immunochromatographic Assay. MOLECULES, 27 (13): (4019). [PMID:35807264] [10.3390/molecules27134019] |
7. Ting Zhou, Guangzhao He, Changjia Hu, Kang Wu, Ying Liu, Jianguo Li, Anping Deng. (2022) Development of a highly sensitive and specific monoclonal antibody-based ELISA coupled with immuno-affinity extraction for the detection of anticancer drug 5-fluorouracil in blood samples. TALANTA, 249 (123655). [PMID:35696979] [10.1016/j.talanta.2022.123655] |
8. Zhouxuan Xiang, Ting Liu, Huimin Wang, Genxin Chen, Xiongbin Zhu, Tonghui Hao, Jiabing Ran, Changying Yang. (2022) Rational design of a supramolecular hydrogel with customizable pH-responsiveness on the basis of pH-induced ionization/protonation transition of BSA. Soft Matter, 18 (16): (3157-3167). [PMID:35380147] [10.1039/D1SM01589C] |
9. Shaoyu Tang, Lei Xu, Xiaolong Yu, Shuona Chen, Huanyong Li, Ying Huang, Junfeng Niu. (2021) Degradation of anticancer drug capecitabine in aquatic media by three advanced oxidation processes: Mechanisms, toxicity changes and energy cost evaluation. CHEMICAL ENGINEERING JOURNAL, 413 (127489). [PMID:] [10.1016/j.cej.2020.127489] |